251 related articles for article (PubMed ID: 23967741)
1. [Dynamic changes in PD-1, TLR3, and TLR4 surface expression on peripheral blood mononuclear cells in chronic hepatitis C patients undergoing peg-IFNalpha-2a plus ribavirin combination therapy].
Zhang M; Jiang YF; Xiao XQ; Liu SF; Peng ML; Liu D; Gong GZ
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):196-201. PubMed ID: 23967741
[TBL] [Abstract][Full Text] [Related]
2. [Dynamic changes in programmed death-1 expression on the surface of T cells in chronic hepatitis C patients undergoing interferon therapy].
Dong RQ; Zhou DF; Han R; Zhou JY; Zhao CY; Zhen Z
Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):899-902. PubMed ID: 24636290
[TBL] [Abstract][Full Text] [Related]
3. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C.
Sadeghi F; Bokharaei-Salim F; Salehi-Vaziri M; Monavari SH; Alavian SM; Salimi S; Vahabpour R; Keyvani H
J Med Virol; 2014 Sep; 86(9):1499-506. PubMed ID: 24889558
[TBL] [Abstract][Full Text] [Related]
4. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.
Villa E; Cammà C; Di Leo A; Karampatou A; Enea M; Gitto S; Bernabucci V; Losi L; De Maria N; Lei B; Ferrari A; Vukotic R; Vignoli P; Rendina M; Francavilla A
J Viral Hepat; 2012 Sep; 19(9):640-9. PubMed ID: 22863268
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
9. [Effect of antiviral treatment on expression of programmed death 1 and programmed death ligand 1 on peripheral T lymphocytes in patients with chronic hepatitis C].
Cai RT; Shen L; Zhao W; Yang YF; Zhang YC
Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):261-6. PubMed ID: 24021786
[TBL] [Abstract][Full Text] [Related]
10. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
11. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients].
Rao H; Yang R; Shang J; Xu X; Chen X; Dou X; Feng Y; Gao Z; Xie Q; Li J; You H; Chen G; Niu J; Gong G; Hou J; Chen H; Zhang D; Wei L
Zhonghua Nei Ke Za Zhi; 2015 Aug; 54(8):699-704. PubMed ID: 26674626
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
[TBL] [Abstract][Full Text] [Related]
15. [Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C].
Wang M; Zheng W; Zhang H; Li Z; Jiang D; Liu Y; Zhou R; Li XG; Zhang Y; Zhang Z; Wu S; Zhang Y; Li J
Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):255-9. PubMed ID: 25173222
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of combination therapy with pegylated-interferon alfa-2a plus ribavirin in autoantibody-positive chronic hepatitis C patients].
Li YX; Yang YJ; Yang M; Chen LY; Lu JJ; Ma YJ; Liu K; Lei XZ; Tang H
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):345-7. PubMed ID: 24025134
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH
Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of T1 response as induced during PEG-IFNalpha plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C.
Trapero M; García-Buey L; Muñoz C; Vitón M; Moreno-Monteagudo JA; Borque MJ; Quintana NE; Moreno-Otero R
Rev Esp Enferm Dig; 2005 Jul; 97(7):481-90. PubMed ID: 16262527
[TBL] [Abstract][Full Text] [Related]
19. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.
Kanda T; Imazeki F; Yonemitsu Y; Mikami S; Takada N; Nishino T; Takashi M; Tsubota A; Kato K; Sugiura N; Tawada A; Wu S; Tanaka T; Nakamoto S; Mikata R; Tada M; Chiba T; Kurihara T; Arai M; Fujiwara K; Kanai F; Yokosuka O
J Viral Hepat; 2011 Jul; 18(7):e292-7. PubMed ID: 21129130
[TBL] [Abstract][Full Text] [Related]
20. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
Zeuzem S; Sulkowski MS; Lawitz EJ; Rustgi VK; Rodriguez-Torres M; Bacon BR; Grigorescu M; Tice AD; Lurie Y; Cianciara J; Muir AJ; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG;
Gastroenterology; 2010 Oct; 139(4):1257-66. PubMed ID: 20600013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
